SinghSKhannaDKalraS.Minocycline and doxycycline: more than antibiotics. Curr Mol Pharmacol. 2021;14(6):1046-1065. doi:10.2174/1874467214666210210122628.
ThamSNKwokYKChanHL.Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol. 1996;132(9):1134-1135. doi:10.1001/archderm.1996.03890330150036.
4.
MaciagMCWardSLO’ConnellAEBroylesAD.Hypersensitivity to tetracyclines: skin testing, graded challenge, and desensitization regimens. Ann Allergy Asthma Immunol. 2020;124(6):589-593. doi:10.1016/j.anai.2020.02.007.
5.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154.
6.
SmithKLeydenJJ.Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329-1342. doi:10.1016/j.clinthera.2005.09.005.
7.
InomataN.Recent advances in drug-induced angioedema. Allergol Int. 2012;61(4):545-557. doi:10.2332/allergolint.12-RAI-0493.